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Abstract
Background: There is limited evidence, so far, as to the optimal management of women with a
prior obstetric history of antepartum complications attributed to thrombosis. We aimed to
investigate the contribution of close antepartum surveillance on pregnancy outcome among
women with prior antepartum complications attributed to thrombosis.
Methods: The study was conducted on all women who were delivered, conceived and delivered
again between January 2000 and January 2006 at a university teaching hospital. Women included
were managed in previous pregnancy at a low risk setting and had unpredicted antepartum
complications occurring at a gestational age of 23 weeks or more. Antepartum complications
considered were intrauterine fetal death, neonates who were small for gestational age, severe pre-
eclampsia and placental abruption. All women were tested for the presence of thrombophilia after
delivery. In the following pregnancy, only women found to have any thrombophilia (thrombophilic
group) were treated with enoxaparin. Both the thrombophilic group and the non-thrombophilic
group (tested negatively for thrombophilia) were managed and observed closely at our high-risk
pregnancy clinic.
Results: Ninety-seven women, who conceived at least once after the diagnosis of the relevant
antepartum complications, were included in this study. Forty-nine had any thrombophilia and 48
tested negatively. Composite antepartum complications (all antepartum complications considered)
were reduced significantly after close antepartum surveillance in both groups. Mean birth weight
and mean gestational age improved significantly and were comparable between the groups.
Conclusion: Close antepartum surveillance may contribute to improvement in the perinatal
outcomes of women with prior antepartum complications attributed to thrombosis.
Background
Severe pre-eclampsia, intrauterine growth restriction,
intrauterine fetal death, and placental abruption affect 8%
of pregnant women and collectively contribute to the larg-
est proportion of maternal and fetal mortality and mor-
bidity [1]. Evidence has accumulated to suggest that these
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antepartum complications could have a common throm-
bogenic basis that manifested in the placenta as placental
infarction, perivillous fibrin deposition, intervillous
thrombosis and placental floor infarction [2,3]. Although
acquired and inherited thrombophilia had been reported
to increase significantly the incidence of antepartum com-
plications attributed to thrombosis [4-8], Mousa et al
reported that no different or specific histological pattern
could be identified among women with antepartum com-
plications when thrombophilia positive and throm-
bophilia negative groups were compared [3].
There is limited evidence, so far, as to the optimal man-
agement of women with a prior obstetric history of
antepartum complications attributed to thrombosis.
Since these women are considered at a high risk of an
adverse maternal or fetal outcome in subsequent pregnan-
cies [1], we aim in this study to investigate the possible
beneficial effect of close antepartum surveillance among
these women who conceived and delivered again at our
institution.
Methods
Women who had a previous pregnancy with antepartum
complications occurring at a gestational age of 23 weeks
or more were followed and tested for thrombophilia.
Antepartum complications considered were unexplained
intrauterine fetal death, neonates who were small for ges-
tational age (SGA), severe pre-eclampsia and placental
abruption. SGA was defined as birth weight below the
10th percentile. Severe pre-eclampsia was defined as blood
pressure measuring above 140/90 combined with pro-
teinuria (300 mg/24 h) and accompanied with one or
more of the following complications: worsening blood
pressure to a level above 160/110, HELLP syndrome
(hemolysis, low platelet count and elevated liver
enzymes), persistent severe headache or visual distur-
bances, persistent severe epigastric pain, nausea and vom-
iting, eclampsia, pulmonary edema, oligouria (urine
output less than 500 cc/24 h), proteinuria of 5 g or more
per 24 h and fetal growth restriction (below the 5th percen-
tile). The study was conducted at a university teaching
hospital on all women who were delivered, tested for
thrombophilia after delivery, conceived and delivered
again between January 2000 and January 2006. Women
were tested for the mutation of guanine to adenine at
nucleotide 1691 in the factor V gene (factor V Leiden), the
mutation of cytosine to thymine at nucleotide 677 in the
gene encoding methylenetetrahydrofolate reductase, and
the mutation of guanine to adenine at nucleotide 20210
in the prothrombin gene. Women were also tested for pro-
tein C, protein S and antithrombin III deficiency; and the
presence of antiphospholipid antibodies (lupus anticoag-
ulant or anticardiolipin antibodies) and the results were
confirmed in a second assay. Blood tests were done six
weeks or more after the previous delivery. Women who
had a previous pregnancy with antepartum complications
that could be attributed to multiple gestations, having
fetuses with major congenital anomalies or chromosomal
abnormalities, fetal infection, chorioamnionitis, hydrops
fetalis and diabetes mellitus were excluded. Only women
found to have any thrombophilia (thrombophilic group)
were treated for the first time, in the following pregnancy,
with the low molecular weight heparin (LMWH), enoxa-
parin (Lovenox, Aventis, France). Enoxaparin was started
after detection of fetal heart activity in the 1st trimester
throughout gestation, and six weeks into the post-partum
period. The enoxaparin dose was 40 mg once daily in
women with a solitary thrombophilia and 80 mg daily
(40 mg every 12 h) in women with combined throm-
bophilia. This higher dose was used based upon the signif-
icantly higher risk for pregnancy loss and stillbirth in
women with combined thrombophilia [9]. Aspirin at a
dose of 100 mg (Aspe'gic nourrissons, Sanofi-Synthe'labo,
France) daily was given in addition to enoxaparin to
women with antiphospholipid antibodies. Additionally,
all women received 5 mg folic acid daily. Both the throm-
bophilic group and the non-thrombophilic group were
managed and observed closely at our high-risk pregnancy
clinic during the study period. Surveillance of both groups
included weekly blood pressure measurements and sono-
graphic estimates of fetal weight at 4 weeks intervals.
When fetal growth restriction (below the 10th percentile)
was detected, sonographic fetal weight estimates were
done every two weeks. In addition, non-stress testing
(NST) twice weekly, umbilical artery Doppler and bio-
physical profile once weekly were also performed.
Women detected to have fetal growth restriction with a
reassuring fetal status were allowed to continue surveil-
lance until term (37 weeks). At 37 – 38 weeks, induction
of labor was considered. Women with a previous intrau-
terine fetal death had a weekly NST starting a week before
the gestational age when fetal death was detected in the
prior pregnancy. These women were induced between 38
– 39 weeks. Women who developed pre-eclampsia or pla-
cental abruption were managed according to the severity
of the disease, fetal status and gestational age. Women
were asked about bleeding episodes, signs of thrombosis,
and symptoms of bone pain. Levels of platelets were fol-
lowed monthly.
We compared perinatal outcomes within and between the
groups before and after close surveillance. Perinatal out-
comes included the reappearance of one or more of the
thrombophilic complications considered (fetal death,
SGA, severe pre-eclampsia and placental abruption), neo-
natal birth weight and Apgar score. Other parameters col-
lected were maternal age and ethnicity. The local
Institutional Review Board approved the study.Reproductive Biology and Endocrinology 2008, 6:55 http://www.rbej.com/content/6/1/55
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Statistical analysis
Data analysis was performed using the SPSS 14 statistical
package (SPSS, Chicago, IL). Comparison of binary varia-
bles between thrombophilic and non-thrombophilic
groups, were analyzed by Chi-square test or Fisher's exact
test as appropriate. T test or Mann Withney test were used
to compare continuous variables between the two inde-
pendent groups. To assess the influence of treatment on
the variables in each group, McNemar, Paired T test or
Wilcoxon signed ranks test were applied as appropriate.
Proportion of live born neonates per woman was calcu-
lated as number of live born neonates divided by number
of births per woman. The same calculation was made
regarding the proportion of preterm deliveries and com-
plicated pregnancies per woman. A p value < 0.05 was
considered significant.
Results
Ninety-seven women, who conceived at least once after
the diagnosis of the relevant antepartum complications,
were included in this study. Of all the 97 women, 49 had
any thrombophilia and 48 tested negatively for throm-
bophilia. Of all the 97 women, 54 were Arabs and 43 were
Jews. Of the 54 Arab women, 34 (63%) had throm-
bophilia compared to 15 out of 43 (35%) Jews (p = 0.008,
OR 3.2, 95% CI 1.4 to 7.3). The thrombophilic profile of
the thrombophilic group is presented in table 1. Thirty-
nine women had a solitary thrombophilic defect, while 10
women had a combined thrombophia. Factor V Leiden
(FVL) was the most common thrombophilic defect, pre-
sented in 16 out of 39 women (41%) as a solitary finding
and in 8 of 10 women (80%) as part of a combined defect.
Among the thrombophilic group, the number of women
with at least one live born neonate was significantly
increased, and the composite antepartum complications
(all antepartum complications considered) were reduced
significantly after close surveillance (table 2). In addition,
the incidence of antepartum complications per woman,
before and after close surveillance combined with LMWH
treatment, was also significantly reduced (table 3). Gesta-
tional age at delivery was 33 weeks (+/- 5.9) compared
with 37.3 weeks (+/- 3.4), (p < 0.01), and the mean birth
weight among women who had live born neonates before
and after close surveillance was 2353 g (+/- 756) and 2869
g (+/- 641) respectively (p < 0.01).
Among the non-thrombophilic group, the number of
women with at least one live neonate was not increased
significantly following close surveillance; however, the
incidence of live born neonates per woman, before and
after close surveillance, was significantly increased (table
2 and 3). Composite antepartum complications were
reduced significantly after close surveillance. The number
of women who had severe pre-eclampsia or delivered
small for age neonates did not differ significantly (table 2
and 3). Gestational age at delivery was 32.4 weeks (+/-
4.8) compared with 36.4 weeks (+/- 3.9) after close sur-
veillance (p < 0.01). The mean birth weight among
women who had live born neonates before and after close
surveillance was 2213 g (+/- 918) and 2592 g (+/- 820)
respectively (p = 0.03). Before close surveillance, all the
parameters studied were comparable between the throm-
bophilic group and the non-thrombophilic group (table
4). After close surveillance, beside the incidence of pre-
term deliveries, each individual antepartum complica-
tions studied was comparable between the groups (table
4). Gestational age and birth weight did not differ
between the groups before and after close surveillance.
Among the thrombophilic group, 19.4% of women deliv-
ered by cesarean section compared to 24.5% among the
non-thrombophilic group after close surveillance (p =
0.5). Of all the vaginal deliveries, 28% and 40% were
induced in the thrombophilic group and the non-throm-
bophilic group respectively (p = 0.3). Three cases of post-
partum bleedings were noticed only within the
thrombophilic group (p = 0.3). Among all live neonates,
none had an Apgar score of less than 7 at 5 minutes in
either group.
Table 1: The thrombophilic profile of the 49 women who belonged to the thrombophilic group.
Single thrombophilia No. Combined thrombophilia No.
Factor V Homozygote 1 Factor V Heterozygote + MTHFR homozygote 4
Factor V Heterozygote 15 Factor V Heterozygote + Protein S deficiency 3
Factor II Homozygote 0 Factor V Homozygote + Protein S deficiency 1
Factor II Heterozygote 5 ANT III deficiency + MTHFR homozygote 1
MTHFR homozygote 7 Protein S deficiency + Protein C deficiency 1
Protein C deficiency 0
Protein S deficiency 3
ANT III deficiency 0
Antiphospholepid antibodies 8
MTHFR = methylenetetrahydrofolate reductase.
ANT = antithrombin.Reproductive Biology and Endocrinology 2008, 6:55 http://www.rbej.com/content/6/1/55
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We did not observe any case of heparin-induced thrombo-
cytopenia among the 49 women treated with LMWH.
Likewise, there were no clinical manifestations of bone
pain or bleeding complications related to LMWH treat-
ment among the women.
Discussion
The present report demonstrates that close antepartum
surveillance at specialized clinics may contribute to
improvement in the perinatal outcomes of women with
prior antepartum complications attributed to thrombosis
regardless of the presence of thrombophilia detected by
our testing methods. Among these women, the incidence
of any thrombophilic defect was 51%, which is, similar to
that reported in the literature [10]. The FVL mutation was
the most common type of thrombophilia, accounting for
49% of all the thrombophilic defects. The incidence of
thrombophilia was significantly higher among Arabs
compared to Jews. The high incidence of thrombophilia
among Israel's Arabs compared to Jews maybe explained
by the high rate of consanguinity reported in that popula-
tion [11,12].
The present report demonstrates that among women with
antepartum complications who were found to have inher-
ited or acquired thrombophilia, close surveillance com-
bined with antithrombotic therapy in subsequent
gestations, resulted in a significant improvement in peri-
natal outcome, compared to the previous gestations. Con-
tradictory reports are present in the literature regarding
the effect and role of LMWH treatment on thrombophilic
women with a history of pre-eclampsia, intrauterine
growth restriction, placental abruption and fetal loss [13-
19]. However, in view of the potential severe conse-
quences of thrombophilia in pregnancy, several reports
have recommended the use of anticoagulant therapy in
the following pregnancies [20,21]. A main issue which
raised in this report is that these pregnancies, once diag-
nosed, are usually managed under close surveillance and,
still, none of these studies had isolated the role of close
antepartum surveillance on pregnancy outcome among
these women. Thus it is still to be determined whether
LMWH alone, close surveillance or both is responsible for
the better outcome.
Table 2: Comparison of perinatal outcomes within the thrombophilic and non-thrombophilic groups before and after close 
surveillance.
Thrombophilic group
(N = 49)
Non-thrombophilic group
(N = 48)
Number of women
with at least one
Before close
surveillance N (%)
After close
surveillance N (%)
P* Before close
surveillance N (%)
After close
surveillance N (%)
P*
Live born neonate 35 (71) 46 (94) 0.004 40 (83) 44(92) 0.1
Preterm delivery 20 (41) 5 (10) 0.001 27 (56) 16 (33) 0.052
Complicated pregnancies 49 (100) 6 (12) <0.001 48 (100) 19 (40) <0.001
SGA 21 (43) 5 (10) <0.001 21 (44) 12 (25) 0.06
IUFD 25 (51) 2 (4) <0.001 20 (42) 3 (6) <0.001
Severe pre-eclampsia 9 (18) 1 (2) 0.02 10 (21) 4 (8) 0.1
Placental abruption 18 (37) 1 (2) <0.001 18 (38) 5 (10) 0.004
* McNemar test
Complicated pregnancies = the reappearance of one or more of the thrombophilic complications considered (fetal death, SGA, severe pre-
eclampsia and placental abruption)
SGA = neonate small for gestational age
IUFD = intrauterine fetal death
Table 3: Comparison of the proportion of complications per woman within the thrombophilic and non-thrombophilic groups before 
and after close surveillance.
Thrombophilic group
(N = 49)
Non-thrombophilic group
(N = 48)
Proportion,
per woman, of
Before close
surveillance
After close
surveillance
P* Before close
surveillance
After close
surveillance
P*
Live born neonate 63 (43) [80] 96 (20) [100] <0.001 74 (38) [100] 96 (21) [100] 0.002
Preterm deliveries 30 (42) [0] 9 (29) [0] 0.01 42 (44) [33] 32 (46) [0] 0.4
Complicated pregnancies 70 (32) [67] 11 (31) [0] <0.001 63 (35) [50] 35 (46) [0] 0.004
The data are presented as mean proportion, (standard deviation) and [median]
* Wilcoxon Signed Rank TestReproductive Biology and Endocrinology 2008, 6:55 http://www.rbej.com/content/6/1/55
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In this study, 49% of the women who had antepartum
complications were tested negatively for thrombophilia
and therefore were not treated with LMWH. After close
surveillance alone in subsequent gestations, a significant
improvement was observed in composite fetal outcome
compared to previous gestations. Nevertheless, and prob-
ably expected, the number of women who had severe pre-
eclampsia or delivered SGA neonates did not differ signif-
icantly with close surveillance alone. Close surveillance
alone, decreased significantly the incidence of IUFDs per
woman. Moreover, gestational age and birth weight were
both improved, probably due to the opportunity of pro-
longing the gestational age under close surveillance.
When comparing perinatal outcome between the groups,
antepartum complications were reduced significantly in
both groups after close surveillance. Moreover, gestational
age at delivery, birth weight and the incidence of live born
neonate per woman were comparable between the
groups.
Comparing the thrombophilic and the non-throm-
bophilic group, who tested negatively for the throm-
bophilic defects studied, might seem ill advised.
Nevertheless, both groups share probably the same utero-
placental histopathology. Mousa et al reported that no
specific histological pattern could be identified among
women with antepartum complications when throm-
bophilia positive and thrombophilia negative groups
were compared and concluded that a poor correlation
exists between thrombophilia status and pathological
changes of the placenta in women with antepartum com-
plications [3]. Moreover, it cannot be ruled out that the
non-thrombophilic group possesses thrombophilic
defects that are unknown or were not studied in this
report [22]. We did not stratify the obtained results with
the level of fasting total homocysteine, because all women
were taking folic acid from at least 1 month before con-
ception [23].
Moreover, we did not examine the maternal plasma levels
of coagulation factor VIII, which had been reported to be
associated with an increased risk for recurrent early preg-
nancy loss [24], or for protein Z deficiency and positive
antiprotein Z antibodies, which had been described to
increase the severity of the prothrombotic phenotype of
FVL [25]. Whether the non-thrombophilic group has an
unrecognized thrombophilia or not, close surveillance
without any other treatment improved their perinatal out-
comes.
Conclusion
Although, and due to ethical issues, the women in both
groups were not randomized and all got the same close
antepartum surveillance, this study reveals that close sur-
veillance at a specialized clinic may improve the perinatal
outcomes of both thrombophilic and non-thrombophilic
women with prior antepartum complications attributed
to thrombosis. However, this study dose not separate the
effect of LMWH and close antepartum surveillance on
pregnancy outcome among the thrombophilic group and
it still needs to be determined whether the additional
treatment of LMWH is better than close surveillance
alone. While this study cannot answer the latter issue, its
results may be considered an intermediate step in allow-
ing placebo to be compared to LMWH during pregnancy
in thrombophilic women with previous placental dys-
function.
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Table 4: Comparison between perinatal outcomes of thrombophilic and non-thrombophilic groups before and after close surveillance
Before close surveillance After close surveillance
Thrombophilic group 
(N = 49)
Non-thrombophilic 
group (N = 48)
P Thrombophilic group 
(N = 49)
Non-thrombophilic 
group (N = 48)
P
Proportion, per woman, of
Live born neonate* 63 (43) [80] 74 (38) [100] 0.2† 96 (20) [100] 96 (21) [100] 0.9†
Preterm deliveries* 30 (42) [0] 42 (44) [33] 0.1† 9 (29) [0] 32 (46) [0] 0.005†
Number of women who 
delivered at least one
SGA (%) 21 (43) 21 (44) 0.9‡ 5 (10) 12 (25) 0.06‡
IUFD (%) 25 (51) 20 (42) 0.4‡ 2 (4) 3 (6) 0.7§
Severe pre-eclampsia (%) 9 (18) 10 (21) 0.8‡ 1 (2) 4 (8) 0.2§
Placental abruption (%) 18 (37) 18 (38) 0.9‡ 1 (2) 5 (10) 0.1§
* The data are presented as mean proportion, (standard deviation) and [median]
† Mann Withney test
‡ Chi-square test
§Fisher's exact test
SGA = neonate small for gestational age
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